The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.
In separate deals announced this past week, the German biotech firm will distribute assays developed by Asuragen, and co-develop, co-manufacture, and co-market assays with Mikrogen.
The company is collaborating with fellow German biotech firm Mikrogen to identify autoantibody signatures typical of various infectious diseases.
The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.
The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.